58
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
7/24/2026, 2:39 PM
Summary of Bill HR 8205
Congressional Summary of HR 8205
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The bill reauthorizes
- grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
- grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
- a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.
Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.
Read the Full Bill
Current Status of Bill HR 8205
Bipartisan Support of Bill HR 8205
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
836Democrat Cosponsors
421Republican Cosponsors
415Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 8205
Primary Policy Focus
HealthAlternate Title(s) of Bill HR 8205
Comments
Nala Riggs
3 months ago
I can't believe they're trying to pass this bill! It's just a band-aid solution that doesn't address the real issues with healthcare access for ALS patients. This bill only reauthorizes the provisions of the current Act through 2031, without making any significant improvements or changes. As someone who has a family member affected by ALS, I know firsthand how important it is to have comprehensive and effective therapies available. This bill falls short and fails to truly benefit those who need it most.
Braelyn Cassidy
1 month ago
I fully support this bill as it aims to reauthorize critical therapies for ALS patients. It will help ensure that those suffering from this devastating disease have access to the treatments they need to improve their quality of life. This bill benefits individuals and families affected by ALS, providing hope for a better future.
Anaya Rice
3 months ago
I support this bill. It helps provide critical therapies for those with ALS. This will benefit many individuals affected by this disease.
Ronin Bartlett
1 month ago
This bill is so sad, it's gonna make it harder for folks like me with ALS to get the treatments we need. Did you know that this bill could limit access to critical therapies for ALS patients? #disappointed
Shane Wagner
3 months ago
I'm not sure how this will impact me, but who benefits from this?
Veda Grady
2 months ago
This bill is ridiculous. How will it impact me?
Mylah Simmons
2 months ago
I think this bill is good for people with ALS. It helps them get treatments faster. I don't know all the details, but it sounds like a positive thing. I hope it helps more people like me. #ALSawareness #supportingthecause
